Key Performance Drivers

The growth was not uniform across all factors, but rather driven by specific levers:

• Price Increases: Contributed approximately 5.5% to the growth.
• New Product Introductions (NPIs): Added 3.2%, showing a shift toward innovation-led revenue.
• Volume Growth: Remained modest at 1.0%, indicating that while people are paying more for newer or adjusted medicines, the actual quantity of units sold is growing slowly.

Therapy & Segment Highlights

• Cardiac (Market Leader): Holds a 14% share of the total market. It grew at 13.2% (MAT), remaining the most stable high-value segment.
• Anti-Diabetic: Growing at 9.9% (MAT), but saw a massive 15.2% surge in monthly value, fueled by premium metabolic therapies.
• Respiratory: Recorded 10.3% growth, benefiting from seasonal triggers and urban air quality concerns.
• Gynaecology: Delivering steady growth in the 6–10% range, with an increasing focus on hormonal health and IVF.
• Anti-Obesity: The breakout segment of 2026, expanding nearly 10x over five years, largely due to the success of GLP-1 agonists.